



Supplementary Figure 3. Cost-effectiveness acceptability curves. Iterations of the cost-effectiveness of empagliflozin versus placebo under different willingness to pay thresholds in Taiwan. The red curve is for the population with add-on empagliflozin; the orange curve is for the population with standard therapy.